Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02848001 · ClinicalTrials.gov registry record · Phase 1
A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 101
- Enrollment target
NCT02848001 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 101 participants.
The verdict
NCT02848001, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 101 participants
- Enrollment target
Study Summary
CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.
Interventions
- DRUG CC-90009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 101 participants |
| Start Date | 2016-11-14 |
| Est. Completion | 2024-04-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02848001
The ClinicalTrials.gov registry entry for NCT02848001 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 101 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CC-90009 is the first listed.
NCT02848001 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02848001 about?
NCT02848001 is a clinical study titled "A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes". CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk myelodysplastic syndrome.
What is the current status of trial NCT02848001?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 101 participants. The study started on 2016-11-14. Estimated completion is 2024-04-11.
What interventions are being tested in trial NCT02848001?
The interventions under investigation include: CC-90009 (DRUG).
Who is sponsoring clinical trial NCT02848001?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.